Valuation: Mabion S.A.

Market Cap 123M 32.32M 28.18M 26.61M 24.16M 45.27M 3.1B 45.46M 319M 1.58B 121M 119M 5.07B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 129M 33.98M 29.63M 27.97M 25.4M 47.59M 3.26B 47.79M 335M 1.66B 128M 125M 5.33B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
67.18%
Yield 2024 *
-
Yield 2025 -
1 day-2.93%
1 week-0.26%
Current month-2.69%
1 month-2.93%
3 months-1.55%
6 months-13.13%
Current year+9.03%
1 week 7.61
Extreme 7.61
8.06
1 month 7.6
Extreme 7.6
8.47
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
110
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member - 2021-02-22
Chairman 60 2021-05-12
Director/Board Member 53 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.93%-0.26%-18.17%-56.51% 32.32M
-0.31%+5.79%+47.13%+99.53% 70.88B
+0.39%+2.06%+39.38%+78.71% 62.49B
+0.50%+7.13%+33.27%+20.02% 26.34B
-3.21%-7.27%-17.10%+370.22% 26.21B
-2.64%-0.69%-0.17%-11.56% 24.13B
+0.71%+8.03%+25.03%-13.74% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.36B
-0.22%+3.99%+45.54%+171.32% 14.46B
+0.73%+1.71%-5.51%+859.68% 14.24B
Average -0.49%+1.54%+31.10%+185.14% 27.49B
Weighted average by Cap. -0.28%+1.49%+35.68%+150.93%

Financials

2024 2025
Net sales 69.02 18.13 15.81 14.93 13.56 25.4 1.74K 25.51 178.85 884.68 68.12 66.61 2.85K 15.76 4.14 3.61 3.41 3.1 5.8 397.26 5.82 40.83 201.97 15.55 15.21 649.87
Net income -6.33M -1.66M -1.45M -1.37M -1.24M -2.33M -160M -2.34M -16.41M -81.19M -6.25M -6.11M -261M -62.61M -16.45M -14.35M -13.55M -12.3M -23.05M -1.58B -23.14M -162M -803M -61.8M -60.43M -2.58B
Net Debt -35.18M -9.24M -8.06M -7.61M -6.91M -12.95M -887M -13M -91.18M -451M -34.73M -33.96M -1.45B 6.32M 1.66M 1.45M 1.37M 1.24M 2.32M 159M 2.33M 16.37M 80.96M 6.23M 6.1M 260M
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
26-09-18 PLN 7.610 -2.93% 55,791
26-09-17 PLN 7.840 -0.38% 25,277
26-09-16 PLN 7.870 -0.51% 11,134
26-09-15 PLN 7.910 -1.12% 18,972
26-09-14 PLN 8.000 +4.85% 74,056

Annual profits - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!